Geron (GERN) Non-Current Debt (2011 - 2026)
Geron's (GERN) quarterly Non-Current Debt came in at $120.1 million in Q2 2026, up 0.96% year-over-year from $119.0 million in Q2 2025, and little changed quarter-over-quarter from $119.8 million in Q1 2026.
Analysis
Geron (GERN) Non-Current Debt (2011 - 2026) Analysis & Trends
Geron has disclosed Non-Current Debt across 8 years of filings, most recently posting $120.1 million for Q2 2026.
- In Q2 2026, Non-Current Debt rose 0.96% year-over-year to $120.1 million; the TTM figure through Jun 2026 stood at $120.1 million (up 0.96% YoY), while the FY2025 annual figure was $119.5 million, up 0.9% from the prior year.
- Non-Current Debt came in at $120.1 million for Q2 2026 at Geron, roughly flat from $119.8 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $120.1 million in Q2 2026 to a low of $11.2 million in Q1 2024.
- Average Non-Current Debt over 5 years is $67.5 million, with a median of $47.7 million recorded in 2022.
- Year-over-year, Non-Current Debt tumbled 78.17% in 2024 and jumped 958.28% in 2025.
- Over 5 years, Non-Current Debt stood at $30.2 million in 2022, then advanced by 16.02% to $35.1 million in 2023, then soared by 238.01% to $118.5 million in 2024, then climbed by 0.9% to $119.5 million in 2025, then increased by 0.49% to $120.1 million in 2026.
- Per Business Quant data, the three most recent Non-Current Debt figures were $120.1 million in Q2 2026, $119.8 million in Q1 2026, and $119.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 120.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 120.13 Mn |
| Mar 31, 2026 | 119.83 Mn |
| Dec 31, 2025 | 119.55 Mn |
| Sep 30, 2025 | 119.26 Mn |
| Jun 30, 2025 | 118.99 Mn |
| Mar 31, 2025 | 118.73 Mn |
| Dec 31, 2024 | 118.48 Mn |
| Sep 30, 2024 | 12.28 Mn |
| Jun 30, 2024 | 36.52 Mn |
| Mar 31, 2024 | 11.22 Mn |
| Dec 31, 2023 | 35.05 Mn |
| Sep 30, 2023 | 29.84 Mn |
| Jun 30, 2023 | 40.80 Mn |
| Mar 31, 2023 | 51.40 Mn |
| Dec 31, 2022 | 30.21 Mn |
| Sep 30, 2022 | 37.80 Mn |
| Jun 30, 2022 | 45.26 Mn |
| Mar 31, 2022 | 50.18 Mn |
| Dec 31, 2021 | 49.83 Mn |
| Sep 30, 2021 | 34.67 Mn |